Table 4.
Clinical Trials of CGM Use in Non-ICU Settings for Adult Patients
| Study | Year | First author country | Patient population | CGM type | CGM manufacturer | Performance measurement | Comparator |
|---|---|---|---|---|---|---|---|
| Dungan et al. [77] | 2012 | USA | T1DM and T2DM (n=58), on intravenous or subcutaneous insulin | iPro system | Medtronic MiniMed | Accuracy | Capillary by POC |
| Burt et al. [78] | 2013 | Australia | T1DM and T2DM, on basal bolus insulin (n=26) | System Gold | Medtronic MiniMed | Accuracy and glycemic control | Capillary by POC |
| Gomez et al. [79] | 2015 | Colombia | T2DM, on basal bolus insulin (n=38) | iPro2 system | Medtronic MiniMed | Glycemic control and hypoglycemia detection | Capillary by POC |
| Schaupp et al. [80] | 2015 | Austria | T2DM, on basal bolus insulin (n=84) | iPro2 system | Medtronic MiniMed | Accuracy | Capillary by POC |
| Spanakis et al. [81] | 2018 | USA | T2DM, on insulin therapy (n=5) | Dexcom G4 CGM with Share2 application | Dexcom | Glucose telemetry system feasibility | None |
| Migdal et al. [82] | 2020 | USA | Adult medicine and surgery patients with T1DM and T2DM (n=49) | Dexcom (CGM type unspecified) | Dexcom | Precision and accuracy | Capillary by POC |
| Shehav-Zaltzman et al. [83] | 2020 | Israel | T1DM on CSII (n: 1) and T2DM on basal bolus (n=3), COVID-19 wards (n=5) | Guardian | Medtronic MiniMed | Feasibility | None |
| Singh et al. [84] | 2020 | USA | T2DM, on basal-bolus insulin (n=13) | Dexcom G4 Platinum CGM | Dexcom | Feasibility and prevention of hypoglycemia | Blinded CGM |
| Tripyla et al. [75] | 2020 | Switzerland | Prediabetes patients undergoing elective abdominal surgery (n=20) | Dexcom G6 | Dexcom | Accuracy | Capillary by POC |
| Reutrakul et al. [85] | 2020 | USA | Diabetes (unspecified type) on subcutaneous insulin injection with COVID-19 (n=1) | Dexcom G6 | Dexcom | Feasibility | Capillary by POC |
| Galindo et al. [86] | 2020 | USA | T2DM, on basal-bolus insulin (n=97) | FreeStyle Libre Pro CGM | Abbott Diabetes Care | Accuracy and hypoglycemia detection | Capillary by POC |
| Nair et al. [76] | 2020 | USA | Surgical ward (n=10) | Dexcom G6 Blinded | Dexcom | Accuracy | Capillary by POC |
| Singh et al. [87] | 2020 | USA | T2DM, on basal-bolus insulin (n=72) | Dexcom G6 | Dexcom | Prevention of hypoglycemia | Blinded CGM |
| Fortmann et al. [88] | 2020 | USA | T2DM on subcutaneous insulin (n=110) | Dexcom G6 | Dexcom | Effectiveness | Capillary by POC |
| Ushigome et al.[89] | 2021 | Japan | Diabetes (unspecified type) with COVID-19 (n=1) | Dexcom G4 Platinum | Dexcom | Safety and effectiveness | Lab |
CGM, continuous glucose monitor; ICU, intensive care unit; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; POC, point of care; CSII, continuous subcutaneous insulin infusion; COVID-19, coronavirus disease 2019.